HomeStructural heart diseaseValvular Aortic valve

Valvular Aortic valve

View Category

Structural heart disease

COAPT: Promising 5-Year Outcomes

Secondary ischemic and non-ischemic mitral valve failure (SMR), produce left ventricle dilation, papillary muscle displacement, and impaired...
solaci -
Learn More
Femoral

TAVR: Vascular Access in Patients with Peripheral Artery Disease, 1-Year Outcomes

At present, the transfemoral access (TFA) is the preferred approach when it comes to transcatheter aortic valve...
solaci -
Learn More
Mitral valve

ACC 2023 | TRILUMINATE Pivotal: Edge-to-Edge Treatment in Patients with Tricuspid Regurgitation

Tricuspid regurgitation is a common and impairing disease. Optimal medical therapy (OMT) is limited, valve surgery is...
solaci -
Learn More
Structural heart disease

ACC 2023 | TAVR in Low Risk Patients: 3-Year Outcomes

At present, transcatheter aortic valve replacement (TAVR) has become the gold standard in the US, regardless surgical...
solaci -
Learn More
Mitral valve

ACC 2023 | COAPT Study: 5 Year Followup after Transcatheter Repair of Secondary Mitral Regurgitation

The five year outcomes of the multicenter open label COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous...
solaci -
Learn More
Structural heart disease

TAVR and New Onset LBBB

The safety and efficacy of transcatheter aortic valve replacement (TAVR) is already established. However, it still poses...
solaci -
Learn More
Structural heart disease

Is Rehospitalization a Relevant Factor after Aortic Valve Replacement?

Patients with severe symptomatic aortic stenosis treated with aortic valve replacement might still present cardiac failure, even...
solaci -
Learn More
Mitral valve

Secondary Mitral Regurgitation: Stages of Heart Failure and Prognostic Implications after Transcatheter Edge-to-Edge Repair

We are already familiar with the strong impact of secondary mitral valve regurgitation (SMR) in survival and...
solaci -
Learn More